Teens with bipolar or schizophrenia get long-term safety check for OLZ/SAM

NCT ID NCT04987229

ENROLLING_BY_INVITATION Disease control Sponsor: Alkermes, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times

Summary

This study looks at the long-term safety of a drug called OLZ/SAM in teenagers with schizophrenia or bipolar I disorder. About 236 teens who finished a previous study can join. Researchers will track side effects over time to see if the drug is safe for ongoing use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Alkermes Investigational Site

Dothan, Alabama, 36303, United States
Alkermes Investigational Site

Little Rock, Arkansas, 72204, United States
Alkermes Investigational Site

Stanford, California, 94305, United States
Alkermes Investigational Site

Washington D.C., District of Columbia, 20010, United States
Alkermes Investigational Site

Miami Lakes, Florida, 33016, United States
Alkermes Investigational Site

Decatur, Georgia, 30030, United States
Alkermes Investigational Site

Chicago, Illinois, 60611, United States
Alkermes Investigational Site

Indianapolis, Indiana, 46202, United States
Alkermes Investigational Site

Saint Charles, Missouri, 63304, United States
Alkermes Investigational Site

Lincoln, Nebraska, 68526, United States
Alkermes Investigational Site

Cincinnati, Ohio, 45229, United States
Alkermes Investigational Site

West Chester, Ohio, 45069, United States
Alkermes Investigational Site

Richmond, Virginia, 23220, United States
Alkermes Investigational Site

Everett, Washington, 98201, United States
Alkermes Investigational Site

Ciudad Autonoma de Buenos Aire, Buenos Aires, C1181ACH, Argentina
Alkermes Investigational Site

La Plata, Buenos Aires, 1900, Argentina
Alkermes Investigational Site

Buenos Aires, Buenos Aires F.D., C1133AAH, Argentina
Alkermes Investigational Site

Mendoza, Mendoza Province, 5500, Argentina
Alkermes Investigational Site

Córdoba, X5003DCE, Argentina
Alkermes Investigational Site

Fortaleza, Ceará, 60430-140, Brazil
Alkermes Investigational Site

Curitiba, Paraná, 80240-280, Brazil
Alkermes Investigational Site

Rio de Janeiro, Rio de Janeiro, 22270-060, Brazil
Alkermes Investigational Site

São Paulo, São Paulo, 05403-010, Brazil
Alkermes Investigational Site

Goiânia, 74093-040, Brazil
Alkermes Investigational Site

São Paulo, 01228-000, Brazil
Alkermes Investigational Site

Barranquilla, 110121, Colombia
Alkermes Investigational Site

Bello, 51053, Colombia
Alkermes Investigational Site

Bogotá, 111166, Colombia
Alkermes Investigational Site

Bogotá, 80020, Colombia
Alkermes Investigational Site

Pereira, 660003, Colombia
Alkermes Investigational Site

León, Guanajuato, 37000, Mexico
Alkermes Investigational Site

Monterrey, Nuevo León, 64620, Mexico
Alkermes Investigational Site

Monterrey, Nuevo León, 64710, Mexico
Alkermes Investigational Site

Culiacán, Sinaloa, 80230, Mexico
Alkermes Investigational Site

Gustavo A. Madero, State of Mexico, C.P. 07000, Mexico
Alkermes Investigator Site

Denver, Colorado, 80202, United States

Conditions

Explore the condition pages connected to this study.

BIPOLAR I DISORDER SCHIZOPHRENIA